March 17, 2026 09:00 Regulatory Valberedningen i Flerie AB föreslår val av en ytterligare styrelseledamot
March 17, 2026 09:00 Regulatory The Nomination Committee of Flerie AB proposes the election of an additional Board member
March 12, 2026 12:30 Regulatory Bolagsverket har lämnat tillstånd att verkställa fusionsplanen mellan Flerie och Lipum
March 12, 2026 12:30 Regulatory The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum
March 10, 2026 16:00 Non Regulatory Fleries portföljbolag Lipum tilldelas bidrag om 8 miljoner euro från Horizon Europe
March 10, 2026 16:00 Non Regulatory Flerie’s portfolio company Lipum selected for EUR 8 million Horizon Europe grant
February 27, 2026 13:00 Non Regulatory Fleries portföljbolag Xspray Pharma utser Blake Leitch till vd och lämnar in uppdaterad FDA-ansökan för Dasynoc®
February 27, 2026 13:00 Non Regulatory Flerie’s portfolio company Xspray Pharma appoints Blake Leitch as CEO and resubmits application for market approval of Dasynoc® to the FDA
February 24, 2026 23:35 Regulatory Flerie’s Board of Directors decides on a directed new share issue of SEK 76 million and proposes a bonus issue and termination of the share redemption programme after this year’s redemption period
February 24, 2026 23:35 Regulatory Fleries styrelse beslutar om riktad nyemission om 76 mkr samt föreslår fondemission och avveckling av aktieinlösenprogrammet efter årets inlösenperiod
February 11, 2026 11:30 Non Regulatory Fleries portföljbolag Microbiotica rapporterar positiva fas 1b-data för MB310 i patienter med ulcerös kolit
February 11, 2026 11:30 Non Regulatory Flerie’s portfolio company Microbiotica reports positive Phase 1b data for MB310 in patients with ulcerative colitis